Login / Signup

Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins.

Janika SchmittEmma PooleIan J GrovesDavid J OwenStephen C GrahamJohn H SinclairBernard T Kelly
Published in: EMBO reports (2024)
The exquisite specificity of antibodies can be harnessed to effect targeted degradation of membrane proteins. Here, we demonstrate targeted protein removal utilising a protein degradation domain derived from the endogenous human protein Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). Recombinant antibodies genetically fused to this domain drive the degradation of membrane proteins that undergo constitutive internalisation and recycling, including the transferrin receptor and the human cytomegalovirus latency-associated protein US28. We term this approach PACTAC (PCSK9-Antibody Clearance-Targeting Chimeras).
Keyphrases
  • endothelial cells
  • cancer therapy
  • cell surface
  • protein protein
  • binding protein
  • induced pluripotent stem cells
  • amino acid
  • pluripotent stem cells
  • drug delivery
  • risk assessment
  • preterm birth
  • life cycle